Takeda launches Adynovate for haemophilia patients

An extended half-life recombinant Factor VIII (rFVIII) treatment for hemophilia A, resulting in lower weekly infusion rates than standard FVIII, providing excellent prophylactic coverage

Takeda Pharmaceutical Company has launched Adynovate, an innovative extended half-life recombinant Factor VIII (rFVIII) treatment, using established technology (controlled PEGylation), for haemophilia A patients.


Adynovate in combination with MYPKFIT, the first and only FDA approved application offers a personalised and interactive prophylaxis treatment option that enables both healthcare professionals (HCPs) and patients in real-time to monitor factor VIII levels.

Alerts are sent to patients on prophylaxis when their estimated factor VIII levels are low and remind them when their infusions are due, thereby providing excellent prophylactic coverage.

Speaking at the launch, Serina Fischer, GM – India, Takeda said, “Patients are at the core of every decision at Takeda and we are committed to increasing the access to our highly innovative treatments that enhances the quality of life for patients here in India. The launch of Adynovate is yet another step to addressing the gaps in haemophilia treatment and assisting healthcare professionals and patients in better management of the condition. We are hopeful that this new treatment offering will help redefine possibilities for haemophilia patients in India.”

Commenting on the benefits of prophylaxis for haemophilia A patients, Dr Sandeep Arora, Head of Medical Affairs and Patient Services – India, Takeda, said, “Individuals with severe haemophilia A have recurrent hemarthrosis, fragmentation of joint cartilage, bone destruction, and crippling which can be effectively reduced through prophylaxis as opposed to on-demand therapy. Studies show that an innovative extended half-life, Adynovate, helps patients to reduce dosing and infusion frequency thereby improving treatment adherence while providing personalised prophylactic coverage. Adynovate has been tested in a comprehensive global clinical program demonstrating favourable safety and efficacy results that offer an effective bleed resolution, better joint health, and almost ZERO spontaneous bleeds in the majority.”

Administered in three steps with BAXJECT III system, Adynovate eliminates the need to disinfect the vial, as vials are already assembled in the system housing. It can be stored at room temperature not to exceed 30°C (86°F) for a period of up to three months not to exceed the expiration date thereby easing the handling and storing process.

Support us in our endeavor to bring you Advertisement free content.
Choose your options to donate or subscribe.


Related Articles

Back to top button